Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ishares Msci Spain ETF (EWP) vs Mesoblast Limited (MESO) Price & Performance

Ishares Msci Spain ETFTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Ishares Msci Spain ETF vs Mesoblast Limited — how do they compare? Ishares Msci Spain ETF trades at $62.65, while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Ishares Msci Spain ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.

EWPMESO
Sector
Broad Market / FactorTechnology
52-Week High
$62.66$20.96
52-Week Low
$47.02$12.88
Market Cap
$2.16B
Enterprise Value
$2.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ishares Msci Spain ETF

EWP is trading at $62.66, up 0.58% with a bullish technical signal driven by strong moving average support. The stock shows mixed momentum with overbought RSI readings but positive ADX trend strength. Recent corporate actions include a $0.92 dividend scheduled for June 2026. European market sentiment remains influenced by ECB policy decisions and energy price volatility.

The stock's outlook balances technical strength against fundamental data gaps. European economic resilience and potential short-squeeze dynamics offer upside, while overbought conditions and geopolitical risks present near-term headwinds. Dividend income provides additional shareholder value, though comprehensive financial metrics are needed for full fundamental assessment.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

About Ishares Msci Spain ETF

EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.

Read more on EWP

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO